All In MedTech

Device Trial Radar · NCT06166901

Evaluation of Long-term Safety and Performance of PanOptix Trifocal Intraocular Lens (IOL)

Evaluation of Long-term Safety and Performance of AcrySof PanOptix Trifocal & PanOptix Trifocal Toric Intraocular Lens (IOL)

Last checked: Nov 20, 2026Latest source record: Mar 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

211

Actual

Start

Apr 27, 2024

Primary completion

Feb 5, 2025

Study completion Feb 5, 2025

Sponsor

Lead sponsor
Alcon ResearchNot on our public-company list
Sponsor type
Industry
First posted
Dec 12, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Basic science
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this Post-Market Clinical Follow-up (PMCF) study is to describe the long-term safety and performance of the AcrySof IQ PanOptix IOL toric and non-toric models in subjects bilaterally implanted with these IOLs for 3 to 5 years. This study will be conducted in Spain.

Conditions

  • Aphakia
  • Astigmatism
  • Presbyopia

Interventions

  • AcrySof IQ PanOptix IOL ToricDevice

    Trifocal toric IOL implanted in the capsular bag in the eye for the visual correction of aphakia and pre-existing corneal astigmatism in adult patients with and without presbyopia who desire near, intermediate and distance vision with increased spectacle independence.

  • AcrySof IQ PanOptix IOL Non-ToricDevice

    Trifocal IOL implanted in the capsular bag in the eye for the visual correction of aphakia in adult patients with less than 1.00 diopter of preoperative corneal astigmatism with and without presbyopia who desire near, intermediate and distance vision with increased spectacle independence.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Binocular Best Corrected Distance Visual Acuity (BCDVA)Time frame: Year 3-5 postoperative (Visit 1, Day 1)
  2. Number of Eyes Experiencing an Ocular Adverse Event by ToricityTime frame: Retrospective data from preoperative visit to Year 3-5 postoperative (Visit 1, Day 1)
  3. Number of Subjects Experiencing a Non-Ocular Adverse EventTime frame: Retrospective data from preoperative visit to Year 3-5 postoperative (Visit 1, Day 1)

1 more outcomes with a free account

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Barraquer Ophthalmology Center

    Barcelona, Spain

  • Institut Catala de la Retina - Sarria

    Barcelona, Spain

  • Hospital Arruzafa

    Córdoba, Spain

4 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.